Washington University School of Medicine

Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Study of [(212)Pb]VMT-α-NET for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Retrieved on: 
Wednesday, November 8, 2023
Radiation therapy, Standard of care, DOTATATE, NYSE, Washington University in St. Louis, CATX, European Association of Nuclear Medicine, Mallinckrodt Institute of Radiology, PRRT, Glomus tumor, Tissue, Washington University School of Medicine, SSTR2, European Association for the Study of the Liver, NETS, TAT, Safety, Fast track (FDA), Therapy, Patient, Pharmaceutical industry, Radiology

The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).

Key Points: 
  • The trial is a multi-center, open-label dose escalation, dose expansion study of [212Pb]VMT-α-NET in patients who have not received prior peptide receptor radionuclide therapy (PRRT).
  • “We are proud of our team’s commitment and progress in bringing our radionuclide therapy to patients suffering from these difficult-to-treat neuroendocrine tumors,” said Thijs Spoor, Chief Executive Officer of Perspective Therapeutics.
  • “The development of Perspective’s [212Pb]VMT-α-NET targeted alpha particle therapy is an important next step in the evolution of treatments for SSTR2-expressing tumors.
  • We are excited to participate in the trial.”
    “We are excited about our collaboration with investigators from top-tier research centers who are evaluating [212Pb]VMT-α-NET in patients with intractable SSTR2-expressing neuroendocrine tumors,” said Markus Puhlmann, Chief Medical Officer of Perspective Therapeutics.

Majority of Medical and Nursing Students Planning Careers Outside Patient Care, as Fears of Burnout and Clinician Shortages Leave Them Worried About the Future

Retrieved on: 
Monday, October 30, 2023
Faculty, APRN, Education, RNS, Life, Access, Bureau of Labor Statistics, ChatGPT, Workforce, Health, Bureau, Learning, Health education, Curriculum, Washington University School of Medicine, Pulse, CNE, Medicine, American Hospital Association, Student, Hospital, CHSE, DNP, Retirement, George Washington University School of Nursing, Depression, Future, Nursing, Patient, Pharmaceutical industry, Elsevier, Osmosis, Clinician

Elsevier Health's first global "Clinician of the Future 2023: Education Edition" highlights students' deep concerns about balancing their commitment to patient care with their own well-being. The report also identifies key insights into students' excitement and fears toward technology and AI in healthcare education.

Key Points: 
  • Now, in my fourth year and preparing for the next step of residency training, I am reflecting on the reality of entering the workforce.
  • My peers and I have discussed what our soon-to-be realities might look like between exhausting residency expectations, staff shortages, patient backlogs and the potential toll on our overall well-being.
  • Additionally, the Bureau of Labor Statistics projects there will be 203,200 openings for RNs each year through 2031.
  • Hosting webinars on resilience and depression in healthcare, as well as developing podcast episodes relevant to healthcare challenges

Kronos Bio Presents Positive Preliminary Data from the Phase 1 Dose Escalation Portion of the Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Mechanism of action, Trial of the century, AACR, Vomiting, Lung cancer, Drug, Conference, Doctor of Philosophy, Carcinoma, CDK9, Nausea, KRON, Kronos, Learning, Case Western Reserve University, Ewing sarcoma, Washington University School of Medicine, Neoplasm, Sarcoma, Safety, Cancer, Patient, Neutropenia, SAN, Rhabdomyosarcoma, Fatigue, Pharmaceutical industry, Medicine

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the presentation of positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting in Dublin, Ireland. Today’s presentation by Dr. Van Tine of Washington University School of Medicine includes clinical data that was first presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Massachusetts in the context of pre-clinical models that provide a better understanding of the observed anti-tumor activity. Preclinical studies led by Berkley Gryder, PhD, of Case Western Reserve University demonstrated KB-0742's on-mechanism activity in transcription factor fusion positive models for rhabdomyosarcoma and Ewing sarcoma.

Key Points: 
  • Preclinical studies led by Berkley Gryder, PhD, of Case Western Reserve University demonstrated KB-0742's on-mechanism activity in transcription factor fusion positive models for rhabdomyosarcoma and Ewing sarcoma.
  • Today, I shared a case study on one of my sarcoma patients who exhausted all standard therapies as well as multiple experimental treatments.
  • The preliminary analysis included 28 patients enrolled in a dose escalation study who received doses from 10 mg up to 60 mg (data cut-off September 1st, 2023).
  • To learn more about the preliminary positive KB-0742 data presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Mass.

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Retrieved on: 
Tuesday, October 31, 2023
APLM, Colon, NSCLC, GBM, C-2, Hepatocyte growth factor, Conference, Glioblastoma, SPARTA, WCLC, Washington University School of Medicine, Cancer, HGF, Pancreatic cancer, Brain, Lung cancer, Safety, IST, Patient, MET, EGFR, Pharmaceutical industry

The second new cohort, labeled F, will evaluate vebreltinib monotherapy in histology-agnostic solid tumors with wild type MET gene that have high expression of c-MET and hepatocyte growth factor (HGF).

Key Points: 
  • The second new cohort, labeled F, will evaluate vebreltinib monotherapy in histology-agnostic solid tumors with wild type MET gene that have high expression of c-MET and hepatocyte growth factor (HGF).
  • Dr. Bindiya Patel and Dr. Siddhartha Devarakonda presented this study during a poster session on September 11, 2023, at the World Conference on Lung Cancer (WCLC) in Singapore.
  • A link to the WCLC poster is available under the Investors tab of the Apollomics website at https://www.apollomicsinc.com .
  • It works by inhibiting the aberrant activation of the HGF/c-MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib.

Kronos Bio To Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at the Connective Tissue Oncology Society Annual Meeting

Retrieved on: 
Friday, October 27, 2023
KRON, Cancer, AACR, Washington University School of Medicine, Conference, SAN, Pharmaceutical industry, Mass

SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting being held November 1-4, 2023, in Dublin, Ireland. The presentation will include clinical data that was first presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Mass in the context of pre-clinical models that provide a better understanding of the observed anti-tumor activity.

Key Points: 
  • SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present positive preliminary data from the phase 1 dose escalation portion of the ongoing phase 1/2 KB-0742 study at the Connective Tissue Oncology Society annual meeting being held November 1-4, 2023, in Dublin, Ireland.
  • The presentation will include clinical data that was first presented at the AACR-NCI-EORTC International Conference on October 13, 2023, in Boston, Mass in the context of pre-clinical models that provide a better understanding of the observed anti-tumor activity.
  • Presenter: Brian Van Tine, M.D., of Washington University School of Medicine in St. Louis
    To read the press release on the data presented at the AACR-NCI-EORTC International Conference in Boston, Mass.
  • you may visit https://ir.kronosbio.com/news-releases

Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases

Retrieved on: 
Monday, November 6, 2023
Șaeș, ECHO, Acute myeloid leukemia, Physical examination, Aes, Food, Progression-free survival, ECOG, Wireless ambulatory ECG, Treatment, MD, Eastern Cooperative Oncology Group, PFS, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, HIV disease progression rates, SD, Washington University School of Medicine, Clinical trial, Cardiotoxicity, STS, RECIST, ANN, Safety, Vital signs, Patient, Toxicity, Pharmaceutical industry

HOUSTON, Nov. 6, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced the presentation of preliminary efficacy findings from the Phase 2 portion of the Company's ongoing U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).

Key Points: 
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107).
  • We look forward to further data readouts from this trial and understanding the full potential of Annamycin for the treatment of STS lung mets."
  • The other subject maintained SD through 8 cycles prior to progressing ~6.9 months after initiating treatment with Annamycin.
  • Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases (MB107) visit clinicaltrials.gov and reference identified NCT04887298.

Blue Cross and Blue Shield of Minnesota names Brett Hart, PhD, as Vice President of Behavioral Health and Mental Health Parity

Retrieved on: 
Wednesday, November 1, 2023
Centene Corporation, Mental, White House, SVP, MD, Publication, Psychotherapy, Hart, Optum, Saint Louis University, Blue Cross, Mental health, Washington University School of Medicine, White, Blue Shield, Patient, Nursing, Management

EAGAN, Minn., Nov. 1, 2023 /PRNewswire/ -- Blue Cross and Blue Shield of Minnesota (Blue Cross) today announced that Brett Hart has joined the organization as vice president of behavioral health and mental health parity.

Key Points: 
  • EAGAN, Minn., Nov. 1, 2023 /PRNewswire/ -- Blue Cross and Blue Shield of Minnesota (Blue Cross) today announced that Brett Hart has joined the organization as vice president of behavioral health and mental health parity.
  • In this role, Hart leads enterprise-wide initiatives to optimize Blue Cross' behavioral and mental health services, including health equity goals and mental health parity.
  • Prior to Centene Corporation, Hart held various regional and national clinical operations roles at Optum over the course of 19 years.
  • "His thoughtful approach to transformation and collaboration, combined with proven leadership on advancing mental health issues, makes Brett the right person to be driving the strategic mission and objectives of our Behavioral Health area."

Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Retrieved on: 
Thursday, October 19, 2023
CRISPR, George Washington University School of Medicine & Health Sciences, Safety, Trial of the century, HIV, Washington University School of Medicine, Cell, European Society of Gene and Cell Therapy, Protalix BioTherapeutics, SAN, ESGCT, Pharmaceutical industry

SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, 2023, in Brussels, Belgium.

Key Points: 
  • SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will be held from October 24-27, 2023, in Brussels, Belgium.
  • Dr. Rachel Presti of Washington University School of Medicine, a principal investigator for the clinical evaluation of EBT-101, will offer the first look at interim safety and biodistribution data from the EBT-101-001 Phase 1/2 clinical trial.
  • EBT-101 is being evaluated in a first-in-human clinical study to assess its safety and efficacy in people with HIV on antiretroviral therapy.
  • The presentation details are listed below, and the full program is available on the ESGCT website .

C2N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology

Retrieved on: 
Wednesday, October 25, 2023
Biotechnology, Health, General Health, Pharmaceutical, Neurology, Mental Health, Health Technology, Research, Genetics, Science, Clinical Trials, PSP, Ageing, AD, CSR, Biomarker, Washington University in St. Louis, Therapy, CBD, Lund University, Pathology, Non-fungible token, PET, RUO, Washington University School of Medicine, Partnership, Risk assessment, DRS, Frontotemporal dementia, Brain, Diagnosis, Technology management, FTD, Corticobasal degeneration, Nature Medicine, Medical imaging, Medical device

The MTBR-tau fluid biomarker can be used in the diagnosis of AD, in disease staging, and in the development of tau-directed therapeutics.

Key Points: 
  • The MTBR-tau fluid biomarker can be used in the diagnosis of AD, in disease staging, and in the development of tau-directed therapeutics.
  • The RUO test availability allows leading industry and clinician researchers to further study ways to better diagnose, monitor investigational treatment responses, and understand AD’s underlying biological mechanisms.
  • Dr. David M. Holtzman, the Barbara Burton and Reuben M. Morriss III Distinguished Professor of Neurology, co-founded C2N with Dr. Bateman.
  • C2N is a leader in advancing innovative clinical diagnostics to improve the early diagnosis and treatment of Alzheimer’s disease, and our collaboration enables Washington University discoveries to become commercialized globally.”

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Retrieved on: 
Saturday, October 14, 2023
Incidence, Skull, Finger, BMD, Skeleton, George Washington University School of Medicine & Health Sciences, Pediatrics, Washington University School of Medicine, Bone fracture, Risk, The, Caregiver, Society, Ageing, American Society for Bone and Mineral Research, Fracture, Headache, Mineral, Pediatric emergency medicine, Face, OI, Annual general meeting, Patient, Medical imaging, Medicine, Ultragenyx

NOVATO, Calif., VANCOUVER, British Columbia and LONDON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab (UX143) significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density (BMD). The data were presented in a late-breaker presentation at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR).

Key Points: 
  • In the 2 years prior to treatment with setrusumab all patients experienced at least 1 fracture.
  • Following initiation of treatment with setrusumab, 20 patients experienced no radiographic-confirmed fractures, and 4 patients experienced 7 radiographic-confirmed fractures in 5 separate events.
  • The global, seamless Phase 2/3 Orbit study is evaluating the effect of setrusumab on clinical fracture rate in patients aged 5 to
  • All patients will transition to an extension period and receive open-label setrusumab after the Phase 3 primary analysis is complete.